The deep brain stimulators (DBS) market in India is projected to witness an anticipated compound annual growth rate (CAGR) of over 10 per cent by 2033, according to a report on Tuesday.
The report by GlobalData, a data, and analytics company,
attributed the growth to the increasing prevalence of movement disorders in
India. Besides, the inability of many patients to access appropriate surgical
intervention has resulted in a substantial treatment gap.
Deep brain stimulation (DBS) is a treatment widely used for
illnesses including Parkinson's disease, epilepsy, and other neurological
diseases. The system uses an implanted device to send an electrical current
directly to specific parts of the brain. The electrodes generate electrical
impulses that improve brain function.
As per the report, the rechargeable deep brain stimulators market
in India accounts for around 8 per cent of the Asia-Pacific market in 2024.
This has been strengthened by a rising patient base, cost
advantages, skilled neurosurgeons, and an expanding healthcare infrastructure.
“As global life expectancy rises, age-related neurodegenerative
disorders are becoming more prevalent,” said Divya Soni, Medical Devices
Analyst at GlobalData.
“DBS systems have emerged as a treatment for these conditions but
are limited by a battery life of 3-5 years, requiring periodic surgical
replacement for non-rechargeable models, thus increasing patient burden and
surgical risks,” Soni added.
Soni noted that although DBS devices serve as an effective
treatment option for patients with movement disorders, they present notable
shortcomings.
She pointed out the need to introduce
“advanced DBS technologies that offer a transformative solution in providing
personalised, data-driven therapy,” Soni said. This will set new standards in
precision care, and improve quality of life across the country.
No comments:
Post a Comment